中国新药杂志

托法替布治疗类风湿关节炎的快速卫生技术评估

PDF下载

李若茗 ¹^,² , 解染 ¹ , 田欣 ¹^,² , 董秀 ¹^,² , 陈超阳 ¹^,² , 马凌云 ¹ , 刘晓 ¹ , 周颖 ¹^,² , 崔一民 ¹^,²

中国新药杂志 | 药物安全与合理应用 2021,30(5): 462-469

收起

中国新药杂志 |药物安全与合理应用 2021 , 30 (5) : 462 -469

托法替布治疗类风湿关节炎的快速卫生技术评估

全屏

李若茗¹^,², 解染¹, 田欣¹^,², 董秀¹^,², 陈超阳¹^,², 马凌云¹, 刘晓¹, 周颖¹^,², 崔一民¹^,²

作者信息

¹北京大学第一医院药学部，北京　100034

²北京大学医学部药学院药事管理与临床药学系，北京　100191

通讯作者:

刘晓，女，硕士，主要从事临床药学研究。联系电话：（010）66110802，E-mail：lovefaye1016@126.com。

作者简介:

李若茗，女，硕士研究生，主要从事临床药学研究。联系电话：（010）66110802，E-mail：liruoming96@163.com。

Health technology assessment of tofacitinib in the treatment of rheumatoid arthritis

Ruo-ming LI¹^,², Ran XIE¹, Xin TIAN¹^,², Xiu DONG¹^,², Chao-yang CHEN¹^,², Ling-yun MA¹, Xiao LIU¹, Ying ZHOU¹^,², Yi-min CUI¹^,²

Affiliations

¹Department of Pharmacy, Peking University First Hospital, Beijing 100034, China

²Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

出版时间: 2021-03-15

文章导航

摘要

收起

目的：

利用快速卫生技术评估（health technology assessment，HTA）的方法，定量地评价托法替布用于类风湿关节炎（RA）患者的有效性、安全性、经济性，针对托法替布在临床应用的实际情况，为临床实践、药物遴选和准入决策提供循证证据。

方法：

系统检索2019年5月31日前发表的HTA报告、系统评价/Meta分析和药物经济学研究，检索的数据库及网站包括HTA的各官方网站、英文数据库（PubMed和the Cochrane Library）、中文数据库如中国知网（CNKI）、万方和维普。

结果：

研究纳入HTA报告0篇，Meta分析21篇以及经济学研究3篇。结果显示托法替布单药或联合甲氨蝶呤治疗，可以明确地提高RA患者的ACR缓解率、健康评估问卷（HAQ）评分等疗效的指标，也没有增加严重感染等不良事件的发生率，并且托法替布可以更低的成本为患者带来更高的生活质量。

结论：

托法替布与生物制剂类药物的有效性与安全性相似，并且可以更好地节约成本，提高患者的用药依从性。

关键词

托法替布 / 类风湿关节炎 / 卫生技术评估

Abstract

收起

Objective:

To quantitatively evaluate the efficacy, safety, and economic characteristics of tofacitinib for the treatment of rheumatoid arthritis (RA) patients by using the method of health technology assessment (HTA) and to provide evidence for medication selection and decision making based on the actual application of tofacitinib in clinical practice.

Methods:

The HTA reports, systematic reviews/Meta analyses, and pharmacoeconomic researches published before May 31, 2019 were systematically searched. The databases and websites we searched included HTA official websites, English databases (PubMed and the Cochrane Library), and Chinese databases such as China Knowledge Network (CNKI), Wanfang and Weipu.

Results:

No HTA reports, but 21 Meta-analyses and 3 economic studies were included in this study. The results show that tofacitinib alone or combined with methotrexate treatment can clearly improve the efficacy of ACR, HAQ scores and other indicators of patients with RA, while the incidence of adverse events such as severe infections did not significantly increase. It can bring higher quality of life to patients with lower cost.

Conclusion:

Tofacitinib and biologics are similar in efficacy and safety, and can improve patient medication compliance with a lower cost.

Key words

tofacitinib / rheumatoid arthritis / health technology assessment

引用本文

李若茗, 解染, 田欣, 董秀, 陈超阳, 马凌云, 刘晓, 周颖, 崔一民. 托法替布治疗类风湿关节炎的快速卫生技术评估. 中国新药杂志, 2021 , 30 (5) : 462 -469 .

Ruo-ming LI, Ran XIE, Xin TIAN, Xiu DONG, Chao-yang CHEN, Ling-yun MA, Xiao LIU, Ying ZHOU, Yi-min CUI. Health technology assessment of tofacitinib in the treatment of rheumatoid arthritis[J]. Chinese Journal of New Drugs, 2021 , 30 (5) : 462 -469 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

LITTLEJOHN EA, MONRAD SU. Early diagnosis and treatment of rheumatoid arthritis[J]. Prim Care, 2018, 45(2): 237-255.

[2]

田新平, 曾小峰. 依托指南, 规范类风湿关节炎的诊治, 贯彻达标治疗[J]. 中华内科杂志, 2018(4): 240-241.

[3]

BERMAN S, BUCHER J, KOYFMAN A, et al. Emergent complications of rheumatoid arthritis[J]. J Emerg Med, 2018, 55(5): 647-658.

[4]

中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018(4): 242-251.

[5]

SHEA BJ, REEVES BC, WELLS G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008.

[6]

HUSEREAU D, DRUMMOND M, PETROU S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement[J]. Eur J Health Econ, 2013, 14(3): 367-372.

[7]

BAE SC, LEE YH. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials[J]. Z Rheumatol, 2019, 78(6): 559-567.

[8]

BECHMAN K, SUBESINGHE S, NORTON S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(10): 1755-1766.

[9]

BERGRATH E, GERBER RA, GRUBEN D, et al. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis[J]. Int J Rheumatol, 2017, 3(9): 1-15.

[10]

BUCKLEY F, FINCKH A, HUIZINGA TW, et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis[J]. J Manag Care Spec Pharm, 2015, 21(5): 409-423.

[11]

CAMEAN-CASTILLO M, GIMENO-BALLESTER V, RIOS-SANCHEZ E, et al. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients[J]. J Clin Pharm Ther, 2019, 44(3): 384-396.

[12]

CHOY E, FREEMANTLE N, PROUDFOOT C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses[J]. RMD Open, 2019, 5(1): e000798.

[13]

CHOY E, FREEMANTLE N, PROUDFOOT C, et al. Indirect treatment comparison of the efficacy and safety of sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs[J]. Adv Ther, 2019, 36(4): 817-827.

[14]

HAZLEWOOD GS, BARNABE C, TOMLINSON G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2016(8): CD010227.

[15]

LEE YH, BAE SC, SONG GG. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials[J]. Rheumatol Int, 2015, 35(12): 1965-1974.

[16]

HUANG F, LUO ZC. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Rheumatol, 2019, 38(2): 523-534.

[17]

SINGH JA, HOSSAIN A, TANJONG GE, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis[J]. Cochrane Database Syst Rev, 2016(5): CD012183.

[18]

SINGH JA, HOSSAIN A, TANJONG GE, et al. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)[J]. Cochrane Database Syst Rev, 2016(11): CD012437.

[19]

SINGH JA, HOSSAIN A, MUDANO AS, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis[J]. Cochrane Database Syst Rev, 2017(5): CD012657.

[20]

SOUTO A, MANEIRO JR, SALGADO E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies[J]. Rheumatology, 2014, 53(10): 1872-1885.

[21]

SOUTO A, SALGADO E, MANEIRO JR, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis[J]. Arthritis Rheumatol, 2015, 67(1): 117-127.

[22]

STRAND V, AHADIEH S, FRENCH J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials[J]. Arthritis Res Ther, 2015, 17: 362.

[23]

SUBESINGHE S, BECHMAN K, RUTHERFORD AI, et al. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis[J]. J Rheumatol, 2018, 45(6): 733-744.

[24]

TARP S, ERIC FURST D, BOERS M, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis[J]. Rheumatology (Oxford), 2017, 56(3): 417-425.

[25]

VENERITO V, LOPALCO G, CACCIAPAGLIA F, et al. A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis[J]. Clin Rheumatol, 2019, 38(5): 1309-1317.

[26]

VIEIRA MC, ZWILLICH SH, JANSEN JP, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis[J]. Clin Ther, 2016, 38(12): 2628-2641.

[27]

CLAXTON L, JENKS M, TAYLOR M, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States[J]. J Manag Care Spec Pharm, 2016, 22(9): 1088-1102.

[28]

CLAXTON L, TAYLOR M, GERBER RA, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States[J]. Curr Med Res Opin, 2018, 34(11): 1991-2000.

[29]

CLAXTON L, TAYLOR M, SOONASRA A, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. payer perspective[J]. J Manag Care Spec Pharm, 2018, 24(10): 1010-1017.

[30]

张静, 董晓蕾, 蔡辉. 类风湿关节炎合并心血管疾病的研究进展[J]. 安徽医药, 2018, 22(1): 8-12.

[31]

SINGH JA, SAAG KG, BRIDGES SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis[J]. Arthritis Rheumatol, 2016, 68(1): 1-26.

[32]

HODGE JA, KAWABATA TT, KRISHNASWAMI S, et al. The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2016, 34(2): 318-328.

[33]

LOUDER AM, SINGH A, SAVERNO K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis[J]. Am Health Drug Benefits, 2016, 9(2): 84-93.

2021年第30卷第5期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-29
出版时间：2021-03-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-06-05

基金

作者信息

¹北京大学第一医院药学部，北京　100034

²北京大学医学部药学院药事管理与临床药学系，北京　100191

通讯作者:

刘晓，女，硕士，主要从事临床药学研究。联系电话：（010）66110802，E-mail：lovefaye1016@126.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322627804894704220

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT